WST
West Pharmaceutical Services Inc Health Care Surgical & Medical Instruments & Apparatus S&P 500Russell 3000
$412.62Close
$29.7BMarket cap
$230.63 – $416.6752-week range
Late-januaryNext report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 90 · stronger than 90% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high 1% below its 52-week high
- Earnings growing EPS +57% year on year, faster than the quarter before (+38 pts)
Cautions
- Extended 4.9 ATR above its 50-day average
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
1%
1wk
up 5.2%
price change
1mo
up 11.3%
price change
12-month return
up 49%
market up 11% ·
its own up 34%
F-score
8 / 9
Exceptional
Altman Z
19.27
Low risk
P/E
60.2×
price / earnings
PEG
38.06
P/E / EPS growth
P/B
9.4×
price / book
Earnings yield
up 2.0%
EBIT / enterprise value
Cheaper than
29%
of the market · expensive
Revenue growth
up 6%
year on year
EPS growth
up 57%
latest quarter · +38 pts
Sales growth
up 9%
latest quarter · -5 pts
ROE
up 17%
return on equity
Free cash margin
up 15%
$468.9M FCF
D/E
0.06
long-term debt / equity
Net debt / EBITDA
-0.8×
net cash
Interest cover
38.7×EBIT / interest
Piotroski tests
- took on more long-term debt
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- short-term liquidity improved
- no new shares issued
- gross margin widened
- assets working harder
Repair signals
- Gross margin 34.5% → 35.9%
- Revenue reaccelerating (-2% then +6%)
Trade setup
ATR%
2.5%
$10.31 a day · 2×ATR $391.99
RS
90 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.8×
vs 50-day average
Up/down volume
1.40
50 sessions
Implied move
—
no scheduled report
Trend template · 8 of 8
Screen verdict
-
Stage 2 Leader in mixed conditions
- RS 90
- Trend 8/8
- Off 12-month high 1%
- EPS growth +57% (accel +38 pts)
- Sales growth +9% (accel -5 pts)
- Altman Z 19.27 (low risk)
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Oct 29, 2026
Results reaction
Oct 29, 2026+4% vs market2 sessions after results
Options
$516,40825.3% IV · activity
Financials
- Gross 36%
- Net 16%
- Free cash 15%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $2.1B | $2.8B | $2.9B | $2.9B | $2.9B | $3.1B |
| Gross margin | 36% | 42% | 39% | 38% | 35% | 36% |
| Operating income | $406.9M | $752.3M | $734.0M | $676.0M | $569.9M | $584.9M |
| Net income | $346.2M | $661.8M | $585.9M | $593.4M | $492.7M | $493.7M |
| Net margin | 16% | 23% | 20% | 20% | 17% | 16% |
| Earnings per share | $4.57 | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 |
| Free cash flow | $298.1M | $330.6M | $439.4M | $414.5M | $276.4M | $468.9M |
| Free cash margin | 14% | 12% | 15% | 14% | 10% | 15% |
| Cash | $615.5M | $762.6M | $894.3M | $853.9M | $484.6M | $791.3M |
| Long-term debt | $252.9M | $208.8M | $206.7M | $72.8M | $202.6M | $202.8M |
| Shareholders' equity | $1.9B | $2.3B | $2.7B | $2.9B | $2.7B | $3.2B |
| Shares outstanding | 74m | 74.20m | 74.10m | 73.50m | 72.30m | 72m |
What options price now
- Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology
- $392 – $434 ±5.1% by Nov 20, 2026
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Bigger 25.3% priced · 20.7% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs less
Positioning
- Premium traded
- $516,408 calls $110,208 · puts $406,200 · latest session
- 3.69× +3.64 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls +938 · puts +363 past week
For options traders: ATM IV 25.3% (-17.8% 1w) · 1m ÷ 3m IV 1.05 · 25Δ skew 2.2 pts · Net GEX $1.9M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Jul 23, 2026 | Quarterly ↗ | Jun 30, 2026 | 23d |
| Apr 23, 2026 | Quarterly ↗ | Mar 31, 2026 | 23d |
| Feb 17, 2026 | Annual ↗ | Dec 31, 2025 | 48d |
| Oct 23, 2025 | Quarterly ↗ | Sep 30, 2025 | 23d |
| Jul 24, 2025 | Quarterly ↗ | Jun 30, 2025 | 24d |
| Apr 24, 2025 | Quarterly ↗ | Mar 31, 2025 | 24d |
| Feb 18, 2025 | Annual ↗ | Dec 31, 2024 | 49d |
| Oct 24, 2024 | Quarterly ↗ | Sep 30, 2024 | 24d |
| Jul 25, 2024 | Quarterly ↗ | Jun 30, 2024 | 25d |
| Apr 25, 2024 | Quarterly ↗ | Mar 31, 2024 | 25d |
| Feb 20, 2024 | Annual ↗ | Dec 31, 2023 | 51d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results · Regulation FD ↗ |
| Oct 26, 2026 | Material agreement · Agreement ended · New obligation ↗ |
| Jul 23, 2026 | Results · Regulation FD ↗ |
| Jul 14, 2026 | Material agreement ↗ |
| Jun 1, 2026 | Director or officer change · Regulation FD ↗ |
| May 11, 2026 | Cybersecurity incident · Regulation FD ↗ |
| May 5, 2026 | Shareholder vote ↗ |
| Apr 23, 2026 | Results · Regulation FD ↗ |
| Mar 9, 2026 | Director or officer change · Regulation FD ↗ |
| Feb 12, 2026 | Results · Regulation FD ↗ |
| Oct 23, 2025 | Results · Regulation FD ↗ |
| Sep 11, 2025 | Director or officer change ↗ |